#NewProductAnnouncement

Manufacturing and marketing approval obtained from the Ministry of Health, Labour and Welfare for the Influenza Virus Nucleic Acid Kit "GeneSoC FluA/B Detection Kit," scheduled for sales launch in the first half of fiscal 2026.

Achieved primary endpoints in the Phase III trial of Daridorexant in South Korea; manufacturing and marketing approval application planned for Q1 2026, with approval expected in Q1 2027.